Nitric oxide synthase · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Nitric oxide synthase shows late clinical disease relevance led by Shock. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P29475. Start with Shock, then reuse UniProt P29475 as the stable protein anchor across project notes and exports.
Start with Shock, then reuse UniProt P29475 as the stable protein anchor across project notes and exports.
Nitric oxide synthase shows late clinical disease relevance led by Shock. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Shock because it currently carries late clinical support. Linked drugs include TILARGININE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyNitric oxide synthase 1
Review this target as Nitric oxide synthase, mapped to UniProt P29475. ChEMBL maps the protein component as Nitric oxide synthase 1. Sequence length is 1434 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Nitric oxide synthase as ChEMBL target CHEMBL4630725, mapped to UniProt P29475. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Nitric oxide synthase is the right protein anchor across sources, using UniProt P29475 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Shock is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Nitric oxide synthase |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P29475 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Nitric oxide synthase 1 |
| UniProt Accession | P29475 |
| Component Type | Protein |
| Sequence Length | 1434 aa |
Nitric oxide synthase 1
Review this target as Nitric oxide synthase, mapped to UniProt P29475. ChEMBL maps the protein component as Nitric oxide synthase 1. Sequence length is 1434 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Nitric oxide synthase shows late clinical disease relevance led by Shock. 5 more disease programs remain visible in the same review block.
Start review with Shock because it currently carries late clinical support. Linked drugs include TILARGININE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.